In addition, the effectiveness of this therapy depends on PSMA-mediated uptake of the radioligand; tumours with low or heterogeneous PSMA expression may not receive adequate radiation doses, leading to reduced therapeutic efficacy and prostate-specific antigen (PSA) response [66]. This evidence concerns the gene KLK3 and neoplasm.